Esco Aster Signs Exosome Clinical cGMP Manufacturing Contract With Shine-On Biomedical For A Novel First-In-Class HLA-G Targeting Exosome Drug Delivery Platform
SINGAPORE, Jan. 6, 2026 /PRNewswire/ -- Esco Aster, a vertically integrated cell and derivatives CRDMO based at JTC LaunchPad Singapore, announced CMC manufacturing support for Shine-On Biomedical's HLA-G targeted exosome program. Shine-On...
World's First HLA-G Targeted Exosome Therapy for Cancer Enters U.S. Clinical Trials
FDA Greenlights SOB100 for Phase I; Breakthrough Study Published in Nature Communications TAICHUNG, June 9, 2025 /PRNewswire/ -- A research team led by Dr. Der-Yang Cho, Superintendent of China Medical University Hospital (Taiwan), in collaboration...